Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Nogitecan
Malignant Pancreatic Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Nomlabofusp
Friedreich Ataxia
Larimar Therapeutics, Inc.
P1
CC
(43)
NORVIR
Prostate Adenocarcinoma
University of Chicago
P1
CC
(43)
NORVIR
Prostate Cancer
University of Chicago
P1
CC
(43)
npx267
Metastatic Malignant Neoplasm
NextPoint Therapeutics, Inc.
P1
CC
(43)
npx887
Metastatic Malignant Neoplasm
NextPoint Therapeutics, Inc.
P1
CC
(43)
Nrm-823
Esophageal Squamous Cell Carcinoma
Normunity AccelCo, Inc.
P1
CC
(43)
Nrm-823
Gastroesophageal Junction Adenocarcinoma
Normunity AccelCo, Inc.
P1
CC
(43)
NRT6008
Metastatic Malignant Neoplasm In The Lymph Nodes
Chengdu New Radiomedicine Technology Co. LTD.
P1
CC
(43)
NRT6008
Malignant Pancreatic Neoplasm
Chengdu New Radiomedicine Technology Co. LTD.
P1
CC
(43)
Nst-628
Neoplasm
Nested Therapeutics, Inc
P1
CC
(43)
ntf001
Amyotrophic Lateral Sclerosis
Ruijin Hospital
P1
CC
(43)
ntq2494
Acute Myeloid Leukemia
Nanjing Chia-tai Tianqing Pharmaceutical
P1
CC
(43)
Nuv-868
Breast Neoplasm
Nuvation Bio Inc.
P1
CC
(43)
Nuv-868
Prostate Carcinoma
Nuvation Bio Inc.
P1
CC
(43)
Nuv-868
Castration-Resistant Prostate Carcinoma
Nuvation Bio Inc.
P1
CC
(43)
Nuv-868
Ovarian Neoplasm
Nuvation Bio Inc.
P1
CC
(43)
Nuv-868
Prostate Neoplasm
Nuvation Bio Inc.
P1
CC
(43)
nw-101c
Metastatic Malignant Neoplasm
Neowise Biotechnology
P1
CC
(43)
NW-301D
Neoplasm
Peking University
P1
CC
(43)
nw-301v
Neoplasm
Peking University
P1
CC
(43)
nw-301vt
Neoplasm
Zhejiang University
P1
CC
(43)
nxp800
Ovarian Clear Cell Adenocarcinoma
Nuvectis Pharma, Inc.
P1
CC
(43)
nxp800
Ovarian Clear Cell Tumor
Nuvectis Pharma, Inc.
P1
CC
(43)
nxp900
Lung Adenocarcinoma
Nuvectis Pharma, Inc.
P1
CC
(43)
Showing 3551 to 3575 of 9,920 assets
Previous
Page 143 of 397
Next
